Effect of chenodeoxycholic acid on fibrosis, inflammation and oxidative stress in kidney in high-fructose-fed wistar rats

Kidney and Blood Pressure Research

Volumn 36, Issue 1, 2012, Pages 85-97

  Hu, Zhijuan ^a   Ren, Luping ^b   Wang, Chao ^b   Liu, Bing ^b   Song, Guangyao ^a,b  

^a HEBEI MEDICAL UNIVERSITY   (China)

^b HEBEI GENERAL HOSPITAL   (China)

Author keywords

Chenodeoxycholic acid; Chronic kidney disease; Farnesoid X Receptor; Lipid accumulation

Indexed keywords

CHENODEOXYCHOLIC ACID; CREATININE; FRUCTOSE; GLUCOSE; INTERLEUKIN 6; MESSENGER RNA; NITROGEN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 2; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; UREA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARBOHYDRATE DIET; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG EFFECT; GLOMERULUS BASEMENT MEMBRANE; GLUCOSE BLOOD LEVEL; KIDNEY FIBROSIS; LIPID METABOLISM; MALE; NEPHRITIS; NONHUMAN; OXIDATIVE STRESS; PODOCYTE; PRIORITY JOURNAL; PROTEIN CONTENT; RAT; RENAL PROTECTION; UREA NITROGEN BLOOD LEVEL; URINALYSIS;

ANIMALS; BIOLOGICAL MARKERS; CHENODEOXYCHOLIC ACID; CYTOKINES; DIETARY CARBOHYDRATES; DISEASE MODELS, ANIMAL; FIBROSIS; FRUCTOSE; KIDNEY; LIPID METABOLISM; MALE; MEMBRANE GLYCOPROTEINS; NADPH OXIDASE; NEPHRITIS; OXIDATIVE STRESS; PLASMINOGEN ACTIVATOR INHIBITOR 1; RATS; RATS, WISTAR; RECEPTORS, CYTOPLASMIC AND NUCLEAR; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84865605075     PISSN: 14204096     EISSN: 14230143     Source Type: Journal    
DOI: 10.1159/000341485     Document Type: Article

References (64)

1. Virchow R: Cellular Pathology, as Based Upon Physiological and Pathological Histology 2nd ed. Chance R, Trans. New York, Robert M. Dewitt, 1860, pp 383-408.
2. Kimmelstiel P, Wilson C: Intercapillary lesions in the glomeruli of the kidney. Am J Pathol 1936;12:83-98.
3. Moorhead JF, Chan MK, El-Nahas M, Varghese Z: Lipid nephrotoxicity in chronic progressive glomerular and tubulo-interstitial disease. Lancet 1982;2:1309-1311.
4. Lee HS, Lee JS, Koh HI, Ko KW: Intraglomerular lipid deposition in routine biopsies. Clin Nephrol 1991;36:67-75.
5. Guijarro C, Kasiske BL, Kim Y, O'Donnell MP, Lee HS, Keane WF: Early glomerular changes in rats with dietary-induced hypercholesterolemia. Am J Kidney Dis 1995;26:152-161.
6. Sun L, Halaihel N, Zhang W, Rogers T, Levi M: Role of sterol regulatory element-binding protein 1 in regulation of renal lipid metabolism and glomerulosclerosis in diabetes mellitus. J Biol Chem 2002;277:18919-18927.
7. Ruan XZ, Moorhead JF, Fernando R, Wheeler DC, Powis SH, Varghese Z: Regulation of lipoprotein traf icking in the kidney: role of in lammatory mediators and transcription factors. Biochem Soc Trans 2004;32:88-91.
8. Bray GA, Nielsen SJ, Popkin BM: Consumption of high-fructose corn syrup in beverages may play a role in the epidemic of obesity. Am J Clin Nutr 2004;79:537-543.
9. Jacobson MF: High-fructose corn syrup and the obesity epidemic. Am J Clin Nutr 2004;80:1081-1082.
10. Krilanovich NJ: Fructose misuse, the obesity epidemic, the special problems of the child, and a call to action. Am J Clin Nutr 2004;80:1446-1448.
11. Nakagawa T, Tuttle KR, Short RA, Johnson RJ: Hypothesis: fructoseinduced hyperuricemia as a causal mechanism for the epidemic of the metabolic syndrome. Nat Clin Pract Nephrol 2005;1:80-86.
12. Elliott SS, Keim NL, Stern JS, Teoff K, Havel PJ: Fructose, weight gain, and the insulin resistance syndrome. Am J Clin Nutr 2002;76:911-922.
13. Hwang IS, Ho H, Hoffman BB, Reaven GM: Fructose-induced insulin resistance and hypertension in rats. Hypertension 1987;10:512-516.
14. Bar-On H, Stein Y: Eoffect of glucose and fructose administration on lipid metabolism in the rat. J Nutr 1968;94:95-105.
15. Cohen AM, Teitelbaum A: Eoffect of glucose, fructose, sucrose and starch on lipgenesis in rats. Life Sci 1968;7:23-29.
16. Kasiske BL, O'Donnell MP, Garvis WJ, Keane WF: Pharmacologic treatment of hyperlipidemia reduces glomerular injury in rat 5/6 nephrectomy model of chronic renal failure. Circ Res 1988;62:367-374.
17. Kaufmann NA, Poznanski R, Blondheim SH, Stein Y: Comparison of eoffects of fructose, sucrose, glucose, and starch on serum lipids in patients with hypertriglyceridemia and normal subjects. Am J Clin Nutr 1967;20:131-132.
18. Nikkila EA, Ojala K: Acute eoffects of fructose and glucose on the concentration and removal rate of plasma triglyceride. Life Sci 1966;5:89-94.
19. Zakim D, Pardini R, Herman RH, Sauberlich H: The relation of hepatic-glycerophosphate concentration to lipogenesis in rat liver. Biochim Biophys Acta 1967;137:179-180.
20. Huang YJ, Fang VS, Juan CC, Chou YC, Kwok CF, Ho LT: Amelioration of insulin resistance and hypertension in a fructose-fed rat model with ish oil supplementation. Metabolism 1997;46:1252-1258.
21. Vasdev S, Longerich L, Gill V: Prevention of fructose-induced hypertension by dietary vitamins. Clin Biochem 2004;37:1-9.
22. Nakagawa T, Hu H, Zharikov S, Tuttle KR, Short RA, Glushakova O, Ouyang X, Feig DI, Block ER, Herrera-Acosta J, Patel JM, Johnson RJ: A causal role for uric acid in fructose-induced metabolic syndrome. Am J Physiol Renal Physiol 2006;290:F625-F631.
23. Sanchez-Lozada LG, Tapia E, Jimenez A, Bautista P, Cristobal M, Nepomuceno T, Soto V, Avila-Casado C, Nakagawa T, Johnson RJ, Herrera-Acosta J, Franco M: Fructose-induced metabolic syndrome is associated with glomerular hypertension and renal microvascular damage in rats. Am J Physiol Renal Physiol 2007;292:F423-F429.
24. Gersch MS, Mu W, Cirillo P, Reungjui S, Zhang L, Roncal C, Sautin YY, Johnson RJ, Nakagawa T: Fructose, but not dextrose, accelerates the progression of chronic kidney disease. Am J Physiol Renal Physiol 2007;293: F1256-F1261.
25. Chen J, Muntner P, Hamm LL, Jones DW, Batuman V, Fonseca V, Whelton PK, He J: The metabolic syndrome and chronic kidney disease in US adults.
26. Dominguez JH, Wu P, Hawes JW, Deeg M, Walsh J, Packer SC, Nagase M, Temm C, Goss E, Peterson R: Renal injury: similarities and diofferences in male and female rats with the metabolic syndrome. Kidney Int 2006;69:1969-1976.
27. Kurella M, Lo JC, Chertow GM: Metabolic syndrome and the risk for chronic kidney disease among nondiabetic adults. J Am Soc Nephrol 2005;16:2134-2140.
28. Ziyadeh FN, Hoffman BB, Han DC, Iglesias-De La Cruz MC, Hong SW, Isono M, Chen S, McGowan TA, Sharma K: Long-term prevention of renal insuf iciency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal anti-transforming growth factor-antibody in db/db diabetic mice. Proc Natl Acad Sci USA 2000;97:8015-8020.
29. Makishima M, Okamoto AY, Repa JJ, Tu H, Learned RM, Luk A, Hull MV, Lustig KD, Mangelsdorf DJ, Shan B: Identi ication of a nuclear receptor for bile acids. Science 1999;284:1362-1365.
30. Wang H, Chen J, Hollister K, Sowers LC, Forman BM: Endogenous bile acids are ligands for the nuclear receptor FXR/BAR. Mol Cell 1999;3:543-553.
31. Parks DJ, Blanchard SG, Bledsoe RK, Chandra G, Consler TG, Kliewer SA, Stimmel JB, Willson TM, Zavacki AM, Moore DD, Lehmann JM: Bile acids: natural ligands for an orphan nuclear receptor. Science 1999;284:1365-1368.
32. Chiang JY: Bile acid regulation of gene expression: roles of nuclear hormone receptors. Endocr Rev 2002;23:443-463.
33. Goodwin B, Jones SA, Price RR, Watson MA, McKee DD, Moore LB, Galardi C, Wilson JG, Lewis MC, Roth ME, Maloney PR, Willson TM, Kliewer SA: A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis. Mol Cell 2000;6:517-526.
34. Duran-Sandoval D, Mautino G, Martin G, Percevault F, Barbier O, Fruchart JC, Kuipers F, Staels B: Glucose regulates the expression of the farnesoid X receptor in liver. Diabetes 2004;53:890-898.
35. Ma K, Saha PK, Chan L, Moore DD: Farnesoid X receptor is essential for normal glucose homeostasis. J Clin Invest 2006;116:1102-1109.
36. Stayrook KR, Bramlett KS, Savkur RS, Ficorilli J, Cook T, Christe ME, Michael LF, Burris TP: Regulation of carbohydrate metabolism by the farnesoid X receptor. Endocrinology 2005;146:984-991.
37. Zhang Y, Lee FY, Barrera G, Lee H, Vales C, Gonzalez FJ, Willson TM, Edwards PA: Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice. Proc Natl Acad Sci USA 2006;103:1006-1011.
38. Fiorucci S, Antonelli E, Rizzo G, Renga B, Mencarelli A, Riccardi L, Orlandi S, Pellicciari R, Morelli A: The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver ibrosis. Gastroenterology 2004;127:1497-1512.
39. Hartman HB, Gardell SJ, Petucci CJ, Wang S, Krueger JA, Evans MJ: Activation of farnesoid X receptor prevents atherosclerotic lesion formation in LDLR-/- and apoE-/- mice. J Lipid Res 2009;50:1090-1100.
40. Li YT, Swales KE, Thomas GJ, Warner TD, Bishop-Bailey D: Farnesoid x receptor ligands inhibit vascular smooth muscle cell in lammation and migration. Arterioscler Thromb Vasc Biol 2007;27:2606-2611.
41. Watanabe M, Houten SM, Wang L, Moschetta A, Mangelsdorf DJ, Heyman RA, Moore DD, Auwerx J: Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c. J Clin Invest 2004;113:1408-1418.
42. Zhang Y, Castellani LW, Sinal CJ, Gonzalez FJ, Edwards PA: Peroxisome proliferator-activated receptor-gamma coactivator 1alpha (PGC-1alpha) regulates triglyceride metabolism by activation of the nuclear receptor FXR. Genes Dev 2004;18:157-169.
43. Jiang T, Wang XX, Scherzer P, Wilson P, Tallman J, Takahashi H, Li J, Iwahashi M, Sutherland E, Arend L, Levi M: Farnesoid X receptor modulates renal lipid metabolism, ibrosis, and diabetic nephropathy. Diabetes 2007;56:2485-2493.
44. Thorburn AW, Storlien LH, Jenkins AB, Khouri S, Kraegen EW: Fructose-induced in vivo insulin resistance and elevated plasma triglyceride levels in rats. Am J Clin Nutr 1989;49:1155-1163.
45. Jiang T, Liebman SE, Lucia MS, Phillips CL, Levi M: Calorie restriction modulates renal expression of sterol regulatory element binding proteins, lipid accumulation, and age-related renal disease. J Am Soc Nephrol 2005;16:2385-2394.
46. Bligh Eg, Dyer WJ: A rapid method of total lipid extraction and puri ication. Can J Biochem Physiol 1959;37:911-917.
47. Morooka H, Bonventre JV, Pombo CM, Kyriakis JM, Force T: Ischemia and reperfusion enhance ATF-2 and c-Jun binding to cAMP response elements and to an AP-1 binding site from the c-jun promoter. J Biol Chem 1995;270:30084-30092.
48. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ: Protein measurement with the Folin phenol reagent. J Biol Chem 1951;193:265-275.
49. Keppler A, Gretz N, Schmidt R, Kloetzer HM, Groene HJ, Lelongt B, Meyer M, Sadick M, Pill J: Plasma creatinine determination in mice and rats: an enzymatic method compares favorably with a high-performance liquid chromatography assay. Kidney Int 2007;71:74-78.
50. Hirano T: Lipoprotein abnormalities in diabetic nephropathy. Kidney Int 1999;71:S22-S24.
51. Krolewski AS, Warram JH, Christlieb AR: Hypercholesterolemia-a determinant of renal function loss and deaths in IDDM patients with nephropathy. Kidney Int 1994;45:S125-S131.
52. Browning JD, Horton JD: Molecular mediators of hepatic steatosis and liver injury. J Clin Invest 2004;114:147-152.
53. Horton JD, Shah NA, Warrington JA, Anderson NN, Park SW, Brown MS, Goldstein JL: Combined analysis of oligonucleotide microarray data from transgenic and knockout mice identi ies direct SREBP target genes. Proc Natl Acad Sci USA 2003;100:12027-12032.
54. Okada M, Takemura T, Yanagida H, Yoshioka K: Response of mesangial cells to low-density lipoprotein and angiotensin II in diabetic (OLETF) rats. Kidney Int 2002;61:113-124.
55. Song CY, Kim BC, Hong HK, Kim BK, Kim YS, Lee HS: Biphasic regulation of plasminogen activator/inhibitor by LDL in mesangial cells. Am J Physiol Renal Physiol 2002;283:F423-F430.
56. Lee HS: Oxidized LDL, glomerular mesangial cells and collagen. Diabetes Res Clin Pract 1999;45:117-122.
57. Kalaany NY, Mangelsdorf DJ: LXRS and FXR: the yin and yang of cholesterol and fat metabolism. Annu Rev Physiol 2006;68:159-191.
58. Lee FY, Lee H, Hubbert ML, Edwards PA, Zhang Y: FXR, a multipurpose nuclear receptor. Trends Biochem Sci 2006;31:572-580.
59. Fiorucci S, Rizzo G, Antonelli E, Renga B, Mencarelli A, Riccardi L, Morelli A, Pruzanski M, Pellicciari R: Cross-talk between farnesoid-Xreceptor (FXR) and peroxisome proliferator-activated receptor gamma contributes to the anti ibrotic activity of FXR ligands in rodent models of liver cirrhosis. J Pharmacol Exp Ther 2005;315:58-68.
60. Fiorucci S, Rizzo G, Antonelli E, Renga B, Mencarelli A, Riccardi L, Orlandi S, Pruzanski M, Morelli A, Pellicciari R: A farnesoid x receptor-small heterodimer partner regulatory cascade modulates tissue metalloproteinase inhibitor-1 and matrix metalloprotease expression in hepatic stellate cells and promotes resolution of liver ibrosis. J Pharmacol Exp Ther 2005;314:584-595.
61. Gregory P, Tao J, Mieko I, Zhuowei W, Jinping L, Moshe L: Regulation of renal fatty acid and cholesterol metabolism, in lammation, and ibrosis in Akita and OVE26 mice with type 1 diabetes. Diabete 2006;55:2502-2509.
62. Utimura R, Fujihara CK, Mattar AL, Malheiros DM, Noronha IL, Zatz R: Mycophenolate mofetil prevents the development of glomerular injury in experimental diabetes. Kidney Int 2003;63:209-216.
63. Kim MS, Shigenaga J, Moser A, Feingold K, Grunfeld C: Repression of farnesoid X receptor during the acute phase response. J Biol Chem 2003;278:8988-8995.
64. Wang XX, Jiang T, Shen Y, Adorini L, Pruzanski M, Gonzalez FJ, Scherzer P, Lewis L, Miyazaki-Anzai S, Levi M: The farnesoid X receptor modulates renal lipid metabolism and diet-induced renal in lammation, ibrosis, and proteinuria. Am J Physiol Renal Physiol. 2009;297:F1587-1596.